Media Contact: Beata Mostafavi 734-764-2220
Media Contact: Haley Otman 734 764-2220

Michigan Medicine earns accreditation from the Adult Congenital Heart Association

Michigan Medicine becomes only center in the state to earn ACHA Adult Congenital Heart Disease (ACHD) accreditation

In recognition of its expertise in serving adults with congenital heart disease (CHD), Michigan Medicine, the academic medical center of the University of Michigan, has received accreditation from the Adult Congenital Heart Association (ACHA).

The ACHA, a nationwide organization focused on connecting patients, family members and healthcare providers to form a community of support and network of experts with knowledge of congenital heart disease, is launching its national accreditation program with 11 centers across the U.S.

Individuals with CHD, the most common birth defect diagnosed in one in 100 births, are living longer. There are now 1.4 million adults in the U.S. living with one of the many different types of congenital heart defects that range among simple, moderate, and complex.

“We are excited to be among the first ACHD programs in the country to earn accreditation from the Adult Congenital Heart Association,” says Timothy Cotts, M.D., cardiologist at U-M’s C.S. Mott Children’s Hospital and director of Michigan Medicine’s adult congenital heart disease program at the Frankel Cardiovascular Center. “Accreditation status is reflective of the great cooperation at Michigan Medicine between adult and pediatric cardiology, our commitment to patient and family centered care, and the strength of other programs such as maternal fetal medicine.”

Michigan Medicine received accreditation by meeting ACHA’s criteria, which includes medical services and personnel requirements, and going through a rigorous accreditation process, both of which were developed over a number of years through a collaboration with doctors, physician assistants, nurse practitioners, nurses, and ACHD patients.

“There are now more adults than children in the U.S. with CHD,” said Mark Roeder, President and CEO of ACHA. “Accreditation will elevate the standard of care and have a positive impact on the futures of those living with this disease. Coordination of care is key, and this accreditation program will make care more streamlined for ACHD patients, improving their quality of life.”

About Michigan Medicine: At Michigan Medicine, we create the future of healthcare through the discovery of new knowledge for the benefit of patients and society; educate the next generation of physicians, health professionals and scientists; and serve health needs throughout the state of Michigan and beyond. We pursue excellence every day in our three hospitals, 40 outpatient locations and home care operations that handle more than 2.1 million outpatient visits a year. The U-M Medical School is one of the nation's biomedical research powerhouses, with total research funding of more than $470 million.

About the Adult Congenital Heart Association 

The Adult Congenital Heart Association (ACHA) is a national not-for-profit organization dedicated to improving the quality of life and extending the lives of adults with congenital heart disease (CHD). ACHA serves and supports the more than one million adults with CHD, their families and the medical community—working with them to address the unmet needs of the long-term survivors of congenital heart defects through education, outreach, advocacy, and promotion of ACHD research. For more information about ACHA, contact (888) 921-ACHA. 


The ACHA ACHD Accreditation Program was partially funded by Actelion Pharmaceuticals U.S., Inc. ACHA and Actelion Pharmaceuticals have partnered together since 2007 to support the CHD community.

NOTICE: Except where otherwise noted, all articles are published under a Creative Commons Attribution 3.0 license. You are free to copy, distribute, adapt, transmit, or make commercial use of this work as long as you attribute Michigan Medicine as the original creator and include a link to this article.

Media Inquiries:  734-764-2220 8 a.m.-5 p.m. ET 

734-936-4000 after hours, weekends, and holidays (ask for the PR person on call) for embargoed news, videos & more